H.C. Wainwright Downgrades Relypsa Inc to Neutral

Brokerage firm H.C. Wainwright Downgrades its rating on Relypsa Inc(NASDAQ:RLYP). The shares have been rated Neutral. Previously, the analysts had a Buy rating on the shares. The rating by H.C. Wainwright was issued on Jul 22, 2016.

In a different note, On Jul 21, 2016, Morgan Stanley said it Upgrades its rating on Relypsa Inc. In the research note, the firm Raises the price-target to $9.00 per share. The shares have been rated ‘Equal-weight’ by the firm. On Jul 21, 2016, Brean Capital said it Downgrades its rating on Relypsa Inc. The shares have been rated ‘Hold’ by the firm. On Jul 21, 2016, Citigroup said it Downgrades its rating on Relypsa Inc. In the research note, the firm Raises the price-target to $25.00 per share. The shares have been rated ‘Neutral’ by the firm. On Jun 16, 2016, Wedbush said it Maintains its rating on Relypsa Inc. In the research note, the firm Maintains the price-target to $51.00 per share. The shares have been rated ‘Outperform’ by the firm. On Jun 9, 2016, Wedbush said it Maintains its rating on Relypsa Inc. The shares have been rated ‘Outperform’ by the firm. On Jun 7, 2016, Morgan Stanley said it Downgrades its rating on Relypsa Inc. The shares have been rated ‘Underweight’ by the firm.

Relypsa Inc (RLYP) shares turned negative on Thursdays trading session with the shares closing down -0.02 points or -0.06% at a volume of 19,77,232. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $32.04. The peak price level was also seen at $32.04 while the days lowest was $31.98. Finally the shares closed at $32. The 52-week high of the shares is $34.999 while the 52-week low is $10.26. According to the latest information available, the market cap of the company is $1,432 M.

Relypsa Inc(RLYP) last announced its earnings results on May 4, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $12.38M. Analysts had an estimated revenue of $6.87M. Earnings per share were $-1.26. Analysts had estimated an EPS of $-1.46.

Several Insider Transactions has been reported to the SEC. On Jun 8, 2016, Helen Torley (director) sold 1,013 shares at $19.32 per share price.Also, On Jun 8, 2016, Daniel K Spiegelman (director) sold 1,013 shares at $19.31 per share price.On Jun 8, 2016, Kenneth J. Hillan (director) sold 1,013 shares at $19.31 per share price, according to the Form-4 filing with the securities and exchange commission.

Relypsa Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal cardiovascular and metabolic diseases. The Company’s lead product candidate Patiromer for Oral Suspension (Patiromer FOS) is for the treatment of hyperkalemia a life-threatening condition defined as abnormally elevated levels of potassium in the blood. Its New Drug Application (NDA) for Patiromer FOS was accepted for filing by the United States Food and Drug Administration or FDA. The Company’s NDA is supported by a clinical development program consisting of eight clinical trials: three Phase I trials four Phase II trials and one two-part Phase III trial conducted under a Special Protocol Assessment or SPA. The active ingredient is a cross-linked polymeric bead with a calcium containing counterion. The Company has the global royalty-free commercialization rights to Patiromer FOS.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *